-Cites Risks to Women’s Health
By: Laymah Kollie
Monrovia, Liberia — A group of civil society organizations under the umbrella Amplifying Rights Network (ARN) has warned that ongoing and proposed efforts to tighten restrictions on the sale of Misoprostol could worsen maternal health outcomes and endanger the lives of women and girls across the country, particularly in rural communities where healthcare access is already severely limited.
Misoprostol, commonly known as Cytotec, is a medication primarily used for medical abortions. When combined with mifepristone, misoprostol terminates up to eleven weeks of pregnancy. The drug is used to manage miscarriages, induce labour, treat severe bleeding after childbirth (postpartum bleeding), and prevent stomach ulcers caused by NSAIDs.
In a directive dated April 3, 2026, the Ministry of Health mandated that Misoprostol may only be sold or dispensed with a valid prescription from a licensed physician or authorized prescriber. The ministry further requires the drug to be used under the direct supervision of a licensed pharmacist or authorized professional within an approved facility.
According to the Ministry of Health, the new directive responds to widespread unregulated sale and misuse of Misoprostol. To enforce the regulations, the ministry is collaborating with the Liberia Medicines and Health Products Regulatory Authority (LMHRA), the Liberia Pharmacy Board (LPB), and the Liberia Medical & Dental Council (LMDC).
Under the mandate, health authorities will strengthen supply chain monitoring, inspect pharmaceutical outlets, and verify Misoprostol registration and distribution records. Officials will also ensure pharmacies comply with dispensing guidelines and record-keeping requirements. Authorities will verify prescriber credentials and address professional misconduct involving fraudulent prescriptions. The ministry said it will assist in investigations of illegal distribution and support criminal action where warranted.
However, the decision was received with mixed reviews from the public. In a position statement released Monday, ARN described Misoprostol as a critical, life-saving medication widely recognized for its role in managing postpartum hemorrhage, incomplete miscarriage, and safe abortion care. The network stressed that limiting access to the drug would reverse progress made in addressing Liberia’s high maternal mortality rate, currently estimated at over 1,000 deaths per 100,000 live births.
ARN argued that additional restrictions—such as making the drug strictly prescription-based or limiting its distribution would create dangerous delays in accessing care, particularly in rural communities where healthcare services are already limited. “Access to life-saving interventions is not optional; it is urgent,” the statement emphasized, noting that policy barriers often translate into denied or delayed care for women in remote areas.
The group further pointed to Liberia’s restrictive abortion laws as a contributing factor to unsafe medical practices. According to ARN, the country records an estimated 38,000 abortions annually, many of which occur outside formal health systems. Unsafe abortions, the network noted, account for between 10 and 15 percent of maternal deaths.
“This is a critical lesson, restriction does not stop need, it only makes outcomes more dangerous,” the statement said. ARN highlighted that current regulations already limit access to reproductive health medicines, including Misoprostol and mifepristone, to licensed providers and facilities. In practice, the group said, these controls have driven some women to seek services from informal or unregulated sources, increasing the risk of complications such as sepsis, hemorrhage, and infertility.
The network also warned that further restrictions would disproportionately affect vulnerable populations, including rural women, young people, and low-income families, who often face significant barriers in accessing healthcare services. “Women in urban areas with financial means may still navigate the system, but others will be pushed toward unsafe alternatives,” ARN cautioned, adding that such policies undermine equitable healthcare delivery.
The statement linked the issue to broader challenges within Liberia’s reproductive health system, including limited access to contraceptives, high rates of unintended pregnancies, and persistent gaps in family planning services. ARN urged the Government of Liberia and relevant stakeholders to reject additional restrictions on Misoprostol and instead adopt evidence-based policies that expand safe access at the community level.
Additionally, the Amplifying Rights Network (ARN) also called for increased public education and the empowerment of midwives and community health workers to provide essential care. “Restrictive policies on reproductive health drugs do not protect women; they put them at risk,” the statement concluded. “Protect access, protect health, and protect lives.”
